Avidity biosciences announces oversubscribed $400 million private placement

Funding from new and existing investors, including adage capital partners lp, boxer capital, casdin capital, llc, farallon, janus henderson investors, ra capital management, rtw investments, wellington management, as well as multiple large investment management firms pro forma cash, cash equivalents and investments expected to provide runway into late 2026 avidity to host volume 8 of investor and analyst event series via webcast march 4, 2024, at 8:00 a.m. et to present  aoc 1001 data from marina-ole™ san diego , feb. 29, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that it has agreed to sell 15,224,773 shares of its common stock at a price of $16.50 per share and pre-funded warrants to purchase 9,030,851 shares of its common stock at a price per pre-funded warrant of $16.4990 to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement.
RNA Ratings Summary
RNA Quant Ranking